Companies: 10,795·Total market cap: $144.5T
Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc

FRLNNASDAQHealthcare
$6.49
+$0.01(+0.15%)
Market Cap$28283096
P/E Ratio—
52W High$8.745
52W Low$2.11
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Freeline Therapeutics Holdings plc (FRLN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001810031 · FRLN · NASDAQ · as of Jun 9, 2026

Filing snapshot

135
Total Filings
15-12G
Latest Form
2024-03-01
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001810031 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2023-04-04
Fiscal Year End
Apr 4, 2023
Accession No.
0000950170-23-011688
Primary Document
frln-20221231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001810031 · Accession 0000950170-23-011688

Latest Key Filings

6-KQuarterly Report
6-K
2024-02-20
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2024-03-01
View
EFFECTEFFECT
EFFECT
2024-02-23
View
S-8 POSS-8 POS
S-8 POS
2024-02-22
View
S-8 POSS-8 POS
S-8 POS
2024-02-22
View
S-8 POSS-8 POS
S-8 POS
2024-02-22
View
S-8 POSS-8 POS
S-8 POS
2024-02-22
View
POS AMPOS AM
POS AM
2024-02-22
View
SC 13D/ASC 13D/A
SC 13D/A
2024-02-22
View
SC 13E3/ASC 13E3/A
SC 13E3/A
2024-02-20
View
25-NSE25-NSE
25-NSE
2024-02-20
View
6-KCurrent Report (Foreign Issuer)
6-K
2024-02-20
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-12
View
6-KCurrent Report (Foreign Issuer)
6-K
2024-02-12
View
SC 13G/ABeneficial Ownership Report (Amended)
FREELINE THERAPEUTICS HOLDINGS PLC
2024-01-31
View
Showing 1–15 of 135 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001810031  |  Exchange: NASDAQ · Healthcare

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has submitted 135 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001810031, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Freeline Therapeutics Holdings plc's most comprehensive regulatory disclosure. The most recent Freeline Therapeutics Holdings plc 10-K was filed on 2023-04-04 for fiscal year ending 2023. Historical FRLN 10-K annual reports are available from 2020 through 2023.

Investors researching Freeline Therapeutics Holdings plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
MRNS SEC Filings →ANGN SEC Filings →ALLK SEC Filings →LMNL SEC Filings →ANPC SEC Filings →LSB SEC Filings →ELEV SEC Filings →SER SEC Filings →
→ FRLN Financials→ FRLN Earnings→ FRLN Insider Trades

Frequently Asked Questions

FRLN SEC Filings · 8 questions

Freeline Therapeutics Holdings plc (FRLN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 135 filings and access original documents at no cost. Freeline Therapeutics Holdings plc's CIK is 0001810031.

FRLN SEC filingsFreeline Therapeutics Holdings plc SEC documentsfind FRLN 10-K